NCT02540785

Brief Summary

The aim is to evaluate the short-term changes in ocular surface measures and tear inflammatory mediators after lenticule extraction (FLEx) and small-incision lenticule extraction (SMILE) procedures.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
41

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2014

Shorter than P25 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2014

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

August 31, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 4, 2015

Completed
Last Updated

November 28, 2016

Status Verified

November 1, 2016

Enrollment Period

8 months

First QC Date

August 31, 2015

Last Update Submit

November 24, 2016

Conditions

Keywords

Refractive Surgical Proceduressmall-incision lenticule extractionlenticule extractioninflammatory mediators

Outcome Measures

Primary Outcomes (12)

  • scale of Schirmer I test

    up to 1month after surgery

  • scale of corneal fluorescein staining

    up to 1month after surgery

  • scale of noninvasive tear breakup time

    up to 1month after surgery

  • questionnaire of ocular surface disease index

    up to 1month after surgery

  • scale of central corneal sensitivity

    up to 1month after surgery

  • scale of tear meniscus height

    up to 1month after surgery

  • concentration of Interleukin-1α

    up to 1month after surgery

  • concentration of tumor necrosis factor-α

    up to 1month after surgery

  • concentration of nerve growth factor

    up to 1month after surgery

  • concentration of interferon-γ

    up to 1month after surgery

  • concentration of transforming growth factor-β1

    up to 1month after surgery

  • concentration of matrix metalloproteinase-9

    up to 1month after surgery

Secondary Outcomes (1)

  • Correlation Between Inflammatory Mediators and Ocular Surface Changes

    up to 1month after surgery

Study Arms (2)

lenticule extraction

EXPERIMENTAL

The patients in this group chose to receive the lenticule extraction surgery.

Procedure: lenticule extraction

small-incision lenticule extraction

EXPERIMENTAL

The patients in this group chose to receive the small-incision lenticule extraction surgery.

Procedure: small-incision lenticule extraction

Interventions

Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully

Also known as: 0.3% tobramycin/dexamethasone (TobraDex, Alcon), 0.5% levofloxacin (Cravit, Santen), sodium hyaluronate (HYCOSAN,URSAPHARM Arzneimittel GmbH)
lenticule extraction

Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), make a small incision

Also known as: 0.3% tobramycin/dexamethasone (TobraDex, Alcon), 0.5% levofloxacin (Cravit, Santen), sodium hyaluronate (HYCOSAN,URSAPHARM Arzneimittel GmbH)
small-incision lenticule extraction

Eligibility Criteria

Age18 Years - 25 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • minimum age of 18 years(range from 18 year to 25 years); corneal thickness 500 μm with calculated residual stromal bed after treatment greater than 300 μm; preoperative spherical equivalent refraction between
  • diopter (D) and -6.50 D; preoperative cylindrical equivalent refraction between -0.25 D and -1.50 D; preoperative corneal curvature from 41.0 D to 46.0 D with a regular topographic pattern, verified with an Atlas topographer; monocular best corrected visual acuity of 20/20 or better and stable refractive error (less than 0.5 D change) for 24 months before surgery

You may not qualify if:

  • systemic disease that contraindicated the surgery (such as diabetes, glaucoma and systemic collagen vascular disease); corneal abnormality or disease; a history of tear supplement usage or contact lens wear during the past year

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Zhang C, Ding H, He M, Liu L, Liu L, Li G, Niu B, Zhong X. Comparison of Early Changes in Ocular Surface and Inflammatory Mediators between Femtosecond Lenticule Extraction and Small-Incision Lenticule Extraction. PLoS One. 2016 Mar 3;11(3):e0149503. doi: 10.1371/journal.pone.0149503. eCollection 2016.

MeSH Terms

Conditions

MyopiaAstigmatism

Interventions

TobramycinDexamethasoneTobramycin, Dexamethasone Drug CombinationmethylacetyleneLevofloxacinHyaluronic Acid

Condition Hierarchy (Ancestors)

Refractive ErrorsEye Diseases

Intervention Hierarchy (Ancestors)

NebramycinKanamycinAminoglycosidesGlycosidesCarbohydratesPregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, FluorinatedDrug CombinationsPharmaceutical PreparationsOfloxacinFluoroquinolones4-QuinolonesQuinolonesQuinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsGlycosaminoglycansPolysaccharides

Study Officials

  • Xingwu Zhong, MD PhD

    Zhongshan Ophthalmic Center, Sun Yat-sen University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

August 31, 2015

First Posted

September 4, 2015

Study Start

April 1, 2014

Primary Completion

December 1, 2014

Study Completion

December 1, 2014

Last Updated

November 28, 2016

Record last verified: 2016-11